Skip to main content
Clinical Trials/NCT01375634
NCT01375634CompletedPhase 4

Nasogastric Tube Insertion Using Midazolam in the Emergency Department

University of Vermont1 site in 1 country49 target enrollmentStarted: May 2011Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
49
Locations
1
Primary Endpoint
Pain score on the visual analog scale reported by patient

Study Overview

Brief Summary

Nasogastric tube placement involves insertion of a flexible tube through the nose into the stomach. Placement of the tube can irritate the nose and palate and trigger gagging, causing discomfort, even if topical or local anesthetics are used. This study aims to determine if administration of an ultra-short acting sedative agent (midazolam) into a vein before the procedure, in addition to topical local anesthetic, will decrease the level of discomfort.

Detailed Description

Our overall objective is to improve patient satisfaction with nasogastric (NG) tube placement (placement of a flexible tube through the nose into the stomach) in the emergency department. Placement of an NG tube into the stomach is often performed in the emergency department (ED) setting to evacuate air, blood, or other contents. Generally performed by nursing staff at the bedside in the emergency department, the procedure may produce significant pain and discomfort for the patient despite typical measures including local medications to constrict and numb the nasal mucosa. In one questionnaire of emergency department patients at a large university hospital, placement of an NG tube was reported to be the most painful procedure, ahead of fracture reduction, abscess drainage, and urethral catheterization (Singer et al. 1999). The typical medication used for placement of an NG tube placement is administration of local, topical medications; the use of intravenous drugs to improve patient tolerance of the procedure varies widely in clinical practice (Juhl and Conners 2005). Midazolam (Versed) is an FDA-approved agent for procedural sedation, which has been used frequently at this institution for the placement of NG tubes in the emergency department. In our experience, it facilitates placement by relaxing muscles, thereby decreasing gag, and its anxiolytic and amnestic properties improve patient satisfaction. However, there are no published studies of midazolam for NG tube placement in the ED or any other setting.

The investigators will perform a randomized controlled trial to determine if a single 2mg unit midazolam dose administered intravenously decreases discomfort for patients undergoing nasogastric tube placement in the emergency department. Adult emergency department patients who require NG tubes will be screened and following informed consent they will be randomly assigned to receive either midazolam or saline control. Medications are provided by pharmacy. Registered nurses will perform the placement and administer medications; researcher, nurse and subject will be blinded to the treatment arm. Following the procedure, subjects will be asked to assess their level of discomfort and complete a brief researcher-assisted questionnaire about their experience. The nurse will also complete a questionnaire that addresses the difficulty of the procedure, level of success, and occurrence of unanticipated problems or adverse events. This study may provide support for a clinical practice to improve care for patients requiring NG tube placement in the ED.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Triple (Participant, Care Provider, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • at least 18 years old
  • Receiving a nasogastric tube by a registered nurse at Fletcher Allen Health Care

Exclusion Criteria

  • less than 18 years old
  • weight < 40 kg
  • Need immediate nasogastric tube placement
  • Endotracheal intubation
  • Hemodynamically unstable
  • Non-English speaking
  • Without capacity to provide informed consent

Arms & Interventions

Placebo

Placebo Comparator

Normal saline

Intervention: Midazolam (Drug)

Midazolam

Experimental

Midazolam

Intervention: Midazolam (Drug)

Outcomes

Primary Outcomes

Pain score on the visual analog scale reported by patient

Time Frame: Within 30 minutes after completion of procedure

Degree of pain reported by subject on a visual analog scale and a five point scale

Discomfort score on the visual analog scale reported by patient

Time Frame: Within 30 minutes after completion of procedure

Degree of discomfort reported by subject on a visual analog scale and a five point scale

Secondary Outcomes

  • Difficulty of tube placement(Within 30 minutes after completion of procedure)
  • Complications(Within 30 minutes after completion of procedure)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Kalev Freeman

Assistant Professor

University of Vermont

Study Sites (1)

Loading locations...

Similar Trials